Dive deeper
Open any topic for the full explanation, tables, clinical checkpoints, and references.
Full-length video Where can I learn more about scar expectations after skin cancer treatment?
Why can a scar represent two problems?
A Scar Is the Story of Two Problems
The final appearance reflects both:
- What the cancer required—its size, depth, hidden extension, location, and margin; and
- How the tissue healed—repair method, tension, blood supply, infection, inflammation, skin type, health, and scar biology.
That is why two people with the same treatment name can look different. A one-stage Mohs wound closed in a line, a multi-stage nasal Mohs wound repaired with a flap, and a cheek wound left to heal naturally are all “after Mohs,” but they are not the same scar.
Likewise, “treated with a cream” could describe a small superficial BCC with mild residual pinkness or a large inflammatory field with months of color change.
What scar words should I understand?
The Minimum Vocabulary
Treatment mark
A treatment mark is any lasting visible change after treatment. It may be a surgical scar, pigment change, visible vessels, thinning, firmness, texture change, or a combination.
Linear closure, flap, graft, and natural healing
- A linear closure brings the wound edges together into a line.
- A flap moves nearby skin while preserving its blood supply.
- A graft transfers skin from another site and creates both a recipient-site and donor-site scar.
- Natural healing lets the wound fill and contract without stitches.
Hypertrophic scar and keloid
A hypertrophic scar is raised but stays within the original wound. A keloid extends beyond the wound boundary and can keep growing. Neither should be diagnosed from a photograph alone.1
Pigment change
Hyperpigmentation is darker color; hypopigmentation is lighter color. Inflammation, freezing, radiation, lasers, and scar biology can alter pigment, especially in more deeply pigmented skin.
How do scars change over time?
How Scars Change Over Time
A scar is a moving picture, not a snapshot.
Early
The area may be pink, red, purple, swollen, firm, numb, itchy, tender, crusted, or uneven. Flaps and grafts can look bulky or patch-like before swelling and color settle. Natural-healing and ED&C wounds remain open before they become scars.
Remodeling months
Collagen is reorganized, blood vessels become less prominent, and firmness can soften. A line may flatten. A depressed or grafted area can blend more gradually. Sensation may return unevenly.
Later
Persistent differences in width, height, redness, pigment, texture, contour, tethering, or function become easier to identify. “Later” is not one date. Site, repair, health, and complication history matter.
In a multicenter prospective study of 990 patients after facial Mohs surgery, patient-reported appearance, scar appraisal, symptoms, and quality-of-life measures continued improving through one year.2 That is reassuring but bounded: it does not mean every scar becomes invisible or that every body site and treatment follows the same course.
What appearance is typical after each treatment?
What Appearance Is Typical After Each Treatment?
| Treatment | Common early appearance | Possible longer-term mark | What the treatment name cannot predict |
|---|---|---|---|
| Mohs surgery | Open wound followed by a line, flap, graft, or natural-healing surface; early redness, swelling, firmness | Fine or widened line, contour change, flap or graft color/texture difference, depression, raised scar, or anatomic distortion | Final wound size, repair, number of stages, tumor extension, and individual healing |
| Wide local or standard excision | Incision or temporarily open wound; bruising, swelling, redness | Linear, flap, graft, or natural-healing scar; donor-site scar if grafted | Planned margin, depth, immediate versus delayed repair, pathology result, and tension |
| ED&C | Round raw wound, crust, drainage, gradual filling | Round pale, pink, darker, lighter, shiny, or depressed scar; sometimes raised or uneven | Depth of treatment, body site, wound size, and operator technique |
| Cryotherapy | Redness, swelling, blister, weeping, crust | Light or dark pigment change, smooth or depressed area, textural scar | Freeze depth, cycles, site, and pigment response |
| Topical imiquimod or 5-FU | Treatment-field redness, swelling, crust, erosion, burning, itch | Residual pinkness, darker or lighter pigment, texture change; scar if reaction is deep | Drug, schedule, adherence, reaction depth, and whether cancer persisted |
| PDT | Illumination pain for some patients, redness, swelling, peeling, crust | Persistent redness or pigment change; usually no linear incision | Photosensitizer, light, number of treatments, tumor response, and skin type |
| Radiation | Cumulative redness, dryness, darkening, peeling, tenderness, or open reaction | Pigment change, visible small vessels, thinning, firmness, reduced elasticity, texture change, hair loss, and rarely chronic ulceration | Dose, fractions, technique, field, anatomy, time, and future injury |
| Injection | Needle marks, pain, swelling, redness, inflammation, sometimes ulceration | Pigment, texture, contour, or scar change that depends on the drug and response | The medicine, number of sessions, depth, tumor response, and local reaction |
Why do surgical scars not have one look?
Surgical Scars: Mohs and WLE Do Not Have One Look
Mohs
Mohs examines the properly processed peripheral and deep margin and removes additional tissue only from mapped positive areas. This can preserve uninvolved tissue, which is especially valuable on the eyelid, nose, lip, ear, hand, and other tight anatomy.3
Tissue preservation does not guarantee a tiny or invisible scar. The tumor may extend far beyond the biopsy mark. The final wound may need a long line to close without bunching, a flap to protect a free edge, a graft, or natural healing.
WLE
WLE removes the tumor or biopsy site with a planned clinical margin. A well-designed excision can heal with an excellent line or reconstruction. The scar may be longer than the visible spot because the oncologic margin surrounds the lesion and a closure needs workable geometry.
If a final permanent-section margin is positive, another operation can alter the original repair. Higher-risk cases may therefore use delayed or staged reconstruction, but many appropriate WLE wounds are repaired immediately.
The meaningful comparison
Do not ask only, “Which operation has the smaller scar?” Ask:
- Which method gives this tumor the right margin assessment?
- How much tissue is expected to be removed?
- What repair choices are likely at this site?
- What happens to the repair if the margin is positive?
- Which result protects function as well as appearance?
For recurrent facial BCC, long-term randomized evidence favors Mohs over standard excision for cancer control.4 Avoiding recurrence can itself protect future appearance because recurrent cancer may require a larger second operation.
What can destructive treatments leave behind?
Destructive Treatments: Round Wound, Pigment, and Contour
ED&C
ED&C usually heals as a round or oval open wound. The final site may be pale, pink, darker, lighter, shiny, flat, or depressed. A trunk site may blend differently from the shin, scalp, shoulder, or chest. The method's lack of a designed linear closure is part of the appearance tradeoff.
A small study of 51 patients with superficial truncal BCC tested an adjunctive hydroquinone/tretinoin regimen after ED&C and found only modest, method-dependent cosmetic ratings.5 It does not establish a universal “typical ED&C scar” or justify routine use of that regimen. The honest teaching is that the outcome is variable and site specific.
Cryotherapy
Freezing can injure pigment-producing cells as well as the target. A lighter patch can be particularly noticeable in more deeply pigmented skin. Darkening can also occur after inflammation. Deeper freezing can leave a smooth, thinned, or depressed area.
Neither method should be sold as scar-free. Their best appearance case is a carefully selected superficial tumor in a favorable site, treated to an appropriate depth, that heals without complication or recurrence.
What should I expect after topicals or PDT?
Topicals and PDT: No Incision, but Still a Treatment Field
Imiquimod, 5-FU, and PDT can avoid a surgical line. During treatment, however, the field can become far more visible than the original cancer. Redness, crust, erosion, burning, and swelling can last beyond the final application or light session.
After the surface heals, residual pinkness or pigment change may continue. A smooth final surface can be cosmetically attractive. It still does not provide a complete surgical margin. If the tumor persists or recurs, later surgery can create the scar that the first treatment was intended to avoid.
Appearance therefore cannot be separated from durable tumor control. For superficial BCC, five-year tumor-free survival differed among imiquimod, 5-FU, and PDT, and none of those study arms created a complete margin specimen.6
What should I know about radiation changes?
Radiation: Think Beyond the Last Treatment Day
Radiation can avoid a surgical wound, but it treats an entire field. The cosmetic result can change over time as pigment, small vessels, thickness, elasticity, and fibrosis evolve.7–9
In a randomized study of 347 patients with primary facial BCCs smaller than 4 cm, 87% of surgery-treated patients and 69% of radiation-treated patients rated the cosmetic result as good; four-year tumor failure was also lower after surgery.8 This older trial used several radiation techniques and many surgical cases had frozen-section assessment. It does not describe every modern radiation method. It does refute the assumption that avoiding an incision automatically produces the better appearance.
Radiation remains valuable when surgery is not appropriate or as an adjunct for selected risk. The appearance discussion should include both the early reaction and the long tail.
When is a scar problem modifiable?
Expected Treatment Appearance Versus a Modifiable Scar Problem
| What you see or feel | Often part of expected evolution | A modifiable problem may be present when… |
|---|---|---|
| Redness | New blood vessels and inflammation are prominent early | Redness persists as the dominant concern after adequate maturation or visible vessels remain |
| Firmness | Collagen remodeling can make a new scar feel hard | Firmness remains raised, painful, itchy, tethered, or function limiting |
| Depression or contour difference | Tissue was removed and swelling is changing | The contour remains stable and bothersome after healing, or it distorts a landmark |
| Pigment difference | Inflammation, freezing, radiation, or grafting changes color | The difference persists and a diagnosis-specific pigment strategy is safe |
| Width | A line can temporarily look broader while swollen | It remains widened after maturation or tension has pulled it apart |
| Numbness or tingling | Small skin nerves were cut or stretched | Symptoms are progressive, painful, associated with weakness, or otherwise unexplained |
| Open or bleeding area | Some wounds are still closing under the prescribed plan | It reopens, repeatedly bleeds, fails to heal, or appears after prior closure |
PJL-036 explains which treatment fits each phenotype. The first step is to name the actual problem.
What does the evidence say about scars?
Evidence by the Numbers
Evidence by the NumbersThe early facial Mohs scar is not the final result
The early facial Mohs scar is not the final result
990 patients; improvement through 1 year
- Population
- 990 patients in a multicenter prospective cohort after facial Mohs surgery
- Outcome
- Patient-reported appearance, scar appraisal, symptoms, and quality-of-life measures at baseline, two weeks, six months, and one year
- Time horizon
- One year
What it means: Time is an active part of scar care; appearance and quality of life can continue improving long after the surface closes.
Limitations: This was a facial Mohs cohort with attrition, not a randomized comparison of repair techniques or a prediction that every scar becomes invisible.
References: 2
Evidence by the NumbersAvoiding an incision did not guarantee the better cosmetic rating
Avoiding an incision did not guarantee the better cosmetic rating
87% vs 69%
- Population
- 347 patients randomized for a primary facial BCC smaller than 4 cm; 174 received surgery and 173 received one of several radiation techniques
- Outcome
- Patients rating the cosmetic result as good after surgery versus radiation; four-year tumor failure was 0.7% versus 7.5%
- Time horizon
- Four years
What it means: For these facial BCCs, surgery produced both the stronger tumor-control result and the better patient-rated appearance; “nonsurgical” did not mean cosmetically superior.
Limitations: The trial began in the 1980s, used several older radiation techniques, and 91% of surgical patients had frozen-section examination; it does not rank every modern radiation or surgery method.
References: 8
When does a scar not get a free pass?
A Scar Does Not Get a Free Pass
Most scar changes are not recurrence. Still, contact the treating clinician about:
- a new or enlarging lump;
- a sore that does not heal or repeatedly breaks down;
- recurrent bleeding without a clear cause;
- increasing pain, numbness, tingling, or weakness;
- progressive fixation, firmness, or swelling;
- a new change beside the scar that looks unlike the surrounding skin; or
- eyelid pulling, nostril narrowing, lip distortion, or another functional change.
These signs are not specific for cancer. They are reasons for examination rather than remote reassurance.10,11
What do realistic scar examples show?
Realistic Examples
A red linear scar two months after cheek excision
The line is firm and red but flattening in serial photographs. Time may be the best current treatment. A vascular laser can be discussed later if redness remains the dominant problem.
A pale round mark after cryotherapy
The wound closed, but pigment did not fully return. This is a treatment-related appearance rather than a raised scar. Silicone would not be expected to restore pigment.
A depressed ED&C scar on the upper chest
The site is controlled but lower than the surrounding skin. The problem is contour and texture—not redness or hypertrophic scar. Treatment, if desired, should match that phenotype.
A new bleeding bump at the edge of a radiation field
Do not assume it is a late radiation change. It needs clinical assessment for recurrence, a new skin cancer, or another diagnosis before cosmetic treatment.
Frequently asked questions about treatment scars
Frequently Asked Questions
Why is my surgical scar longer than the spot?
Cancer removal includes a margin, and a round wound often needs a longer line to close without bunching. A longer line can create a smoother final contour than forcing a short closure.
Will the scar disappear?
No treatment can promise an invisible result. A strong outcome is cancer control with preserved function and a scar or treatment mark that becomes comfortable and less noticeable.
Does Mohs guarantee the best cosmetic result?
Mohs offers complete mapped margin assessment and tissue conservation where those advantages matter. Final appearance still depends on tumor extent, wound, repair, anatomy, complications, and healing.
Is a topical treatment cosmetic because it avoids stitches?
Not automatically. It can produce a favorable surface result in selected superficial disease, but the reaction, pigment change, durable control, and rescue plan all matter.
When can I judge the final result?
Look at the direction over months rather than one universal anniversary. Facial Mohs outcomes continued improving through one year in a large prospective cohort, but site and treatment differ.2
Can makeup or camouflage be used while a scar matures?
Often after the surface is adequately healed and the clinician agrees. Products should not be placed on an open or medically unstable area.
What is the best question to bring to a scar visit?
Ask: “Is my main problem redness, height, depression, texture, pigment, width, tethering, function, or something that needs evaluation before scar treatment?”
Where should I go next in the Patient Journey?
Next Steps in the Patient Journey
If the cancer site is stable and the wound has healed enough for scar care, continue to Which Scar Treatments Work Best After Skin Cancer Treatment? That guide ranks options by phenotype and timing rather than pretending one product or procedure is best for every scar.
Continue with the question that fits you now
Who reviewed and authored this scar guide?
References for this scar-expectation guide
References
- Choi C, Mukovozov I, Jazdarehee A, et al. Management of hypertrophic scars in adults: a systematic review and meta-analysis. Australas J Dermatol. 2022;63(2):172-189. PMID: 35099068.
- Veldhuizen IJ, Dusza SW, Kuo A, et al. Patient-reported quality of life and aesthetic satisfaction continues to improve for 1 year after Mohs surgery: a multicenter prospective cohort study. J Am Acad Dermatol. 2025;93(2):444-450. PMID: 40107508. DOI: 10.1016/j.jaad.2025.03.022.
- Tolkachjov SN, Brodland DG, Coldiron BM, et al. Understanding Mohs micrographic surgery: a review and practical guide for the nondermatologist. Mayo Clin Proc. 2017;92(8):1261-1271. PMID: 28778259.
- van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs micrographic surgery for basal cell carcinoma of the face: a randomized clinical trial with 10-year follow-up. Eur J Cancer. 2014;50(17):3011-3020. PMID: 25262378.
- Pariser D, Spencer J, Berman B, et al. Using a hydroquinone/tretinoin-based skin care system before and after electrodesiccation and curettage of superficial truncal basal cell carcinoma: a multicenter, randomized, investigator-blind, controlled study of short-term healing. J Clin Aesthet Dermatol. 2009;2(5):38-43. PMID: 20729963.
- Jansen MHE, Mosterd K, Arits AHMM, et al. Five-year results of a randomized controlled trial comparing photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in superficial basal cell carcinoma. J Invest Dermatol. 2018;138(3):527-533. PMID: 29045820. DOI: 10.1016/j.jid.2017.09.033.
- Likhacheva A, Awan M, Barker CA, et al. Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2020;10(1):8-20. PMID: 31831330. DOI: 10.1016/j.prro.2019.10.014.
- Avril MF, Auperin A, Margulis A, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer. 1997;76(1):100-106. PMID: 9218740. DOI: 10.1038/bjc.1997.343.
- Dadkhahfar S, Farokh P, Demehri S, Nazarian RM. Radiation-induced skin injury: mechanisms, clinical manifestations, and management. Int J Dermatol. 2026;65(5):963-973. PMID: 41201396. DOI: 10.1111/ijd.70127.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer and Squamous Cell Skin Cancer. 2026.
- Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208-250. PMID: 30392755.